These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Teriflunomide for multiple sclerosis. He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682 [TBL] [Abstract][Full Text] [Related]
3. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases. Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325 [TBL] [Abstract][Full Text] [Related]
4. Teriflunomide, a potential novel cause of chronic active colitis. Kővári B; Zachs J; Murchie B; Lauwers GY Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888 [No Abstract] [Full Text] [Related]
5. Rebound syndrome in two cases of MS patients after teriflunomide cessation. Labauge P; Ayrignac X; Prin P; Charif M; Carra-Dalliere C Acta Neurol Belg; 2022 Oct; 122(5):1381-1384. PubMed ID: 35802339 [No Abstract] [Full Text] [Related]
6. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells. Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N Front Immunol; 2021; 12():730342. PubMed ID: 34721394 [TBL] [Abstract][Full Text] [Related]
7. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes. Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880 [TBL] [Abstract][Full Text] [Related]
8. ▼Teriflunomide for multiple sclerosis. Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149 [TBL] [Abstract][Full Text] [Related]
9. Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients? Pourcher V; Yeung J; Le Pimpec-Barthes F; Maillart E; Gibault L; Boussouar S Rev Neurol (Paris); 2022 Mar; 178(3):266-267. PubMed ID: 34579947 [No Abstract] [Full Text] [Related]
10. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis. Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series. Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI; Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197 [TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report. Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096 [TBL] [Abstract][Full Text] [Related]
13. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS. Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M Mult Scler; 2024 Jun; 30(7):833-842. PubMed ID: 38619037 [TBL] [Abstract][Full Text] [Related]
14. "Nail loss after teriflunomide treatment: A new potential adverse event". Mancinelli L; Amerio P; di Ioia M; Di Tommaso V; De Luca G; Onofrj M; Lugaresi A Mult Scler Relat Disord; 2017 Nov; 18():170-172. PubMed ID: 29141803 [TBL] [Abstract][Full Text] [Related]
15. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. Chan A; de Seze J; Comabella M CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290 [TBL] [Abstract][Full Text] [Related]
16. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis. Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594 [TBL] [Abstract][Full Text] [Related]
17. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426 [TBL] [Abstract][Full Text] [Related]
18. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis. Landais A; Alhendi R; Gouverneur A; Teron-Aboud B Mult Scler Relat Disord; 2017 Oct; 17():92-94. PubMed ID: 29055483 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study. Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149 [No Abstract] [Full Text] [Related]
20. An updated review of teriflunomide's use in multiple sclerosis. Miller AE Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]